. 2018 Sep 4;8:13182. doi: 10.1038/s41598-018-31352-2

Table 2.

Relationship between the rs4149056T > C and rs2282143C > T polymorphisms and acitretin efficacy in patients, based on PASI50.

Phase	SLC22A1 Rs2282143C > T						SLCO1B1 Rs4149056T > C
Phase	Genotype/allele	PASI < 50	PASI > 50	P value	OR[95CI]	HWE P value	Genotype/allele	PASI < 50	PASI > 50	P value		HWE P value
Discovery Phase	CC	19	8	P < 0.001	OR:11.875 [2.677,52.670]	P = 0.368	TT	21	13	P = 0.007	OR:8.077 [1.523, 42.834]	P = 0.309
	CT + TT	3	14 + 1	P < 0.001	OR:11.875 [2.677,52.670]		TC	2	10	P = 0.007	OR:8.077 [1.523, 42.834]
	C	41	30	P = 0.002	OR:6.613 [1.759, 24.866]		T	44	36	P = 0.013	OR:6.111 [1.258, 29.693]
	T	3	16	P = 0.002	OR:6.613 [1.759, 24.866]		C	2	10	P = 0.013	OR:6.111 [1.258, 29.693]
Validation Phase	CC	47	27	P = 0.003	OR:3.656 [1.502, 8.897]	P = 0.859	TT	52	37	P = 0.003	OR:8.027 [1.681, 38.338]	P = 0.428
	CT + TT	9 + 1	19 + 2	P = 0.003	OR:3.656 [1.502, 8.897]		TC	4	11	P = 0.003	OR:8.027 [1.681, 38.338]
	C	103	73	P = 0.014	OR:2.622 [1.192, 5.764]		T	108	85	P = 0.028	OR:3.44 [1.075, 11.361]
	T	11	23	P = 0.014	OR:2.622 [1.192, 5.764]		C	4	11	P = 0.028	OR:3.44 [1.075, 11.361]
Total samples	CC	66	35	P < 0.001	OR:5.222 [2.454, 11.111]	P = 0.702	TT	73	50	P < 0.001	OR:5.110 [1.925, 13.561]	P = 0.223
	CT + TT	12 + 1	33 + 3	P < 0.001	OR:5.222 [2.454, 11.111]		TC + TT	6	21	P < 0.001	OR:5.110 [1.925, 13.561]
	C	144	103	P < 0.001	OR:3.895 [2.011, 7.542]		T	152	121	P = 0.001	OR:4.397 [1.721, 11.235]
	T	14	39	P < 0.001	OR:3.895 [2.011, 7.542]		C	6	21	P = 0.001	OR:4.397 [1.721, 11.235]

Notes: In the discovery phase, 45/46 patients were genotyped with rs2282143C > T; in the validation phase, 104/105 patients were genotyped with rs4149056T > C.